Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease

Brain

Volumn 120, Issue 12, 1997, Pages 2187-2195

  Antonini, Angelo ^a   Leenders, Klaus L ^a,b   Vontobel, Peter ^a   Maguire, R Paul ^a   Missimer, John ^a   Psylla, Maria ^a   Günther, Ilonka ^a  

^a PAUL SCHERRER INSTITUTE   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Dopa metabolism; Dopamine D2 receptors; Glucose metabolism; Multiple system atrophy; Parkinson's disease

Indexed keywords

CARBON 11; DOPA; FLUORODEOXYGLUCOSE F 18; GLUCOSE; RACLOPRIDE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DIFFERENTIAL DIAGNOSIS; FEMALE; GLUCOSE METABOLISM; HUMAN; MALE; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; REGRESSION ANALYSIS; SHY DRAGER SYNDROME;

AGED; CARBON RADIOISOTOPES; CAUDATE NUCLEUS; CORPUS STRIATUM; DIAGNOSIS, DIFFERENTIAL; DIHYDROXYPHENYLALANINE; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; HYPOTENSION, ORTHOSTATIC; MALE; MIDDLE AGED; MULTIPLE SYSTEM ATROPHY; NEURONS; PARKINSON DISEASE; PUTAMEN; RACLOPRIDE; RADIOPHARMACEUTICALS; RECEPTORS, DOPAMINE D2; REGRESSION ANALYSIS; SALICYLAMIDES; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0031467450     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/120.12.2187     Document Type: Article

References (41)

1. Anderson TW. An introduction to multivariate statistical analysis. 2nd ed. New York: John Wiley, 1984.
2. Antonini A, Leenders KL, Meier D, Oertel WH, Boesiger P, Anliker M. T2 relaxation time in patients with Parkinson's disease. Neurology 1993a; 43: 697-700.
3. Antonini A, Leenders KL, Reist H, Thomann R, Beer HF, Locher J. Effect of age on D2 dopamine receptors in normal human brain measured by positron emission tomography and [11C]raclopride. Arch Neurol 1993b; 50: 474-80.
4. Antonini A, Schwarz J, Oertel WH, Beer HF, Madeja UD, Leenders KL. [11C]raclopride and positron emission tomography in previously untreated patients with Parkinson's disease: influence of L-dopa and lisuride therapy on striatal dopamine D2-receptors. Neurology 1994; 44: 1325-9.
5. Antonini A, Vontobel P, Psylla M, Guenther I, Maguire RP, Missimer J, et al. Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease. Arch Neurol 1995; 52: 1183-90.
6. Antonini A, Leenders KL, Spiegel R, Meier D, Vontobel P, Weigell-Weber M, et al. Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease. Brain 1996; 119: 2085-95.
7. Brooks DJ, Salmon EP, Mathias CJ, Quinn N, Leenders KL, Bannister R, et al. The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure, and Parkinson's disease, studied with PET. Brain 1990; 113: 1539-52.
8. Brooks DJ, Ibanez V, Sawle GV, Playford ED, Quinn N, Mathias CJ, et al. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with [11C]raclopride and positron emission tomography. Ann Neurol 1992; 31: 184-92.
9. Burn DJ, Sawle GV, Brooks DJ. Differential diagnosis of Parkinson's disease , multiple system atrophy, and Steele-Richardson-Olszewski syndrome: discriminant analysis of striatal 18F-dopa PET data. J Neurol Neurosurg Psychiatry 1994; 57: 278-84.
10. Colosimo C, Albanese A, Hughes AJ, de Bruin VMS, Lees AJ. Some specific clinical features differentiate multiple system atrophy (striatonigral variety) from Parkinson's disease [see comments]. Arch Neurol 1995; 52: 294-8. Comment in: Arch Neurol 1996; 53: 212-3.
11. Colosimo C, Albanese A, Hughes AJ, de Bruin VMS, Lees AJ. Some specific clinical features differentiate multiple system atrophy (striatonigral variety) from Parkinson's disease [see comments]. Arch Neurol 1995; 52: 294-8. Comment in: Arch Neurol 1996; 53: 212-3.
12. De Voider AG, Francart J, Laterre C, Dooms G, Bol A, Michel C, et al. Decreased glucose utilization in the striatum and frontal lobe in probable striatonigral degeneration. Ann Neurol 1989; 26: 239-47.
13. 11C)-labeled raclopride-specific dopamine D2 receptors ligands. J Labelled Comp Radiopharm 1987; 24: 931-9.
14. Eidelberg D, Moeller JR, Dhawan V, Sidtis JJ, Ginos JZ, Strother SC, et al. The metabolic anatomy of Parkinson's disease: complementary [18F]fluorodeoxyglucose and [18F]fluorodopa positron emission tomographic studies. Mov Disord 1990; 5: 203-13.
15. Eidelberg D, Takikawa S, Moeller JR, Dhawan V, Redington K, Chaly T, et al. Striatal hypometabolism distinguishes striatonigral degeneration from Parkinson's disease. Ann Neurol 1993; 33: 518-27.
16. Eidelberg D, Moeller JR, Ishikawa T, Dhawan V, Spetsieris P, Chaly T, et al. Early differential diagnosis of Parkinson's disease with 18F-fluorodeoxyglucose and positron emission tomography. Neurology 1995; 45: 1995-2004.
17. Fearnley JM, Lees AJ. Striatonigral-degeneration: a clinico-pathological study. Brain 1990; 113: 1823-42.
18. Gilman S, Koeppe RA, Junck L, Kluin KJ, Lohman M, St Laurent RT. Patterns of cerebral glucose metabolism detected with positron emission tomography differ in multiple system atrophy and olivopontocerebellar atrophy. Ann Neurol 1994; 36: 166-75.
19. Goto S, Matsumoto S, Ushio Y, Hirano A. Subregional loss of putaminal efferents to the basal ganglia output nuclei may cause parkinsonism in striatonigral degeneration. Neurology 1996; 47: 1032-6.
20. Hamacher K, Coenen HH, Stöcklin G. Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 1986; 27: 235-8.
21. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases [see comments]. J Neurol Neurosurg Psychiatry 1992a; 55: 181-4. Comment in: J Neurol Neurosurg Psychiatry 1993; 56: 938-9.
22. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases [see comments]. J Neurol Neurosurg Psychiatry 1992a; 55: 181-4. Comment in: J Neurol Neurosurg Psychiatry 1993; 56: 938-9.
23. Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study [published erratum appears in Neurology 1992; 42: 1436] [see comments]. Neurology 1992b; 42: 1142-6. Comment in: Neurology 1993; 43: 1629-30.
24. Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study [published erratum appears in Neurology 1992; 42: 1436] [see comments]. Neurology 1992b; 42: 1142-6. Comment in: Neurology 1993; 43: 1629-30.
25. Hughes AJ, Colosimo C, Kleedorfer B, Daniel SE, Lees AJ. The dopaminergic response in multiple system atrophy. J Neurol Neurosurg Psychiatry 1992c; 55: 1009-13.
26. Ito H, Kusaka H, Matsumoto S, Imai T. Striatal efferent involvement and its correlation to levodopa efficacy in patients with multiple system atrophy. Neurology 1996; 47: 1291-9.
27. Leenders KL, Palmer AJ, Quinn N, Clark JC, Firnau G, Garnett ES, et al. Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography. J Neurol Neurosurg Psychiatry 1986; 49: 853-60.
28. Leenders KL, Salmon EP, Tyrrell P, Perani D, Brooks DJ, Sager H, et al. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease. Arch Neurol 1990; 47: 1290-8.
29. Morrish PK, Sawle GV, Brooks DJ. Regional changes in [18F]dopa metabolism in the striatum in Parkinson's disease. Brain 1996a; 119: 2097-103.
30. Morrish PK, Sawle GV, Brooks DJ. An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. Brain 1996b; 119: 585-91.
31. Papp MI, Lantos PL. The distribution of oligodendroglial inclusions in multiple system atrophy and its relevance to clinical symptomatology. Brain 1994; 117: 235-43.
32. Patlak CS, Blasberg RG. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J Cereb Blood Flow Metab 1985; 5: 584-90.
33. Quinn N. Multiple system atrophy-the nature of the beast. [Review]. J Neurol Neurosurg Psychiatry 1989; 52 Special Suppl: 78-89.
34. Quinn NP, Marsden CD. The motor disorder of multiple system atrophy. J Neurol Neurosurg Psychiatry 1993; 56: 1239-42.
35. Rajput AH, Rozdilsky B, Rajput A. Accuracy of clinical diagnosis in parkinsonism-a prospective study. Can J Neurol Sci 1991; 18: 275-8.
36. Reddy GN, Häberli M, Beer HF, Schubiger AP. An improved synthesis of no-carrier-added (NCA) 6-[18F]fluoro-L-DOPA and its remote routine production for PET investigations of dopaminergic systems. Appl Radiat Isot 1993; 44: 645-9.
37. Sawle GV, Wroe SJ, Lees AJ, Brooks DJ, Frackowiak RSJ. The identification of presymptomatic parkinsonism: clinical and [18F]dopa positron emission tomography studies in an Irish kindred. Ann Neurol 1992; 32: 609-17.
38. Sawle GV, Playford ED, Brooks DJ, Quinn N, Frackowiak RSJ. Asymmetrical pre-synaptic and post-synaptic changes in the striatal dopamine projection in dopa naïve parkinsonism. Brain 1993; 116: 853-67.
39. Sawle GV, Playford ED, Burn DJ, Cunningham VJ, Brooks DJ. Separating Parkinson's disease from normality: discriminant function analysis of fluorodopa F18 positron emission tomography data. Arch Neurol 1994; 51: 237-43.
40. Snow BJ, Tooyama I, McGeer EG, Yamada T, Calne DB, Takahashi H, et al. Human positron emission tomographic [18F]fluorodopa studies correlate with dopamine cell counts and levels. Ann Neurol 1993; 34: 324-30.
41. Vingerhoets FJG, Schulzer M, Calne DB, Snow BJ. Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion? Ann Neurol 1997; 41: 58-64.